Integrated Filing — IndAS



General information about company

Scrip Code 500126
NSE Symbol PGHL
MSEI Symbol NOTLISTED
ISIN INE199A01012
Name of company PROCTER & GAMBLE HEALTH LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 26-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 27-03-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Half Yearly
Reporting Quarter Yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 26-05-2026   14:10:00
End date and time of board meeting 26-05-2026   15:35:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 26-05-2026
Indicate Company website link for updated RPT policy of the Company www.pghlhealthindia.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 37,045.00 1,40,797.00
Other income 400.00 1,734.00
Total income 37,445.00 1,42,531.00
2 Expenses
(a) Cost of materials consumed 8,519.00 30,733.00
(b) Purchases of stock-in-trade 2,231.00 7,058.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,463.00) (1,283.00)
(d) Employee benefit expense 5,086.00 22,256.00
(e) Finance costs 21.00 55.00
(f) Depreciation, depletion and amortisation expense 617.00 2,359.00
(f) Other Expenses
1 Other Expenses 9,113.00 36,367.00
Total other expenses 9,113.00 36,367.00
Total expenses 24,124.00 97,545.00
3 Total profit before exceptional items and tax 13,321.00 44,986.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 13,321.00 44,986.00
6 Tax expense
7 Current tax 3,211.00 11,849.00
8 Deferred tax 650.00 446.00
9 Total tax expenses 3,861.00 12,295.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 9,460.00 32,691.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 9,460.00 32,691.00
17 Other comprehensive income net of taxes (293.00) (28.00)
18 Total Comprehensive Income for the period 9,167.00 32,663.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,660.00 1,660.00
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 50,795.00
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 56.99 196.94
Diluted earnings (loss) per share from continuing operations 56.99 196.94
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 56.99 196.94
Diluted earnings (loss) per share from continuing and discontinued operations 56.99 196.94
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above audited financial results for the quarter and financial year ended March 31, 2026 have been reviewed by the Audit Committee and taken on record in the meeting of the Board of Directors held on May 26, 2026. These financial results have been subjected to an audit by the statutory auditors of the Company, who have expressed an unmodified opinion thereon. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. 3. The Board of Directors of the Company, on January 23, 2025, approved the change of the Financial Year end from June 30th to March 31st. Accordingly, the previous Financial Year of the Company viz., 2024-25 was for a period of nine months commencing on July 1, 2024, and ending on March 31, 2025. Due to this change of period, the figures of the current period are not comparable with those of the previous year. 4. The figures for the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of financial year ended March 31, 2026 and the limited reviewed year to date figures up to nine months period ended December 31, 2025 of the current Financial Year . 5. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided. 6. The Board of Directors at its meeting held today, May 26, 2026, have recommended payment of final dividend of Rs. 45 per equity share of 10 each, aggregating to Rs. 7470 lakhs. Said final dividend is subject to approval of the shareholders of the Company at the ensuing 59th Annual General Meeting. Accordingly, total dividend for the financial year (including interim dividend and one-time special dividend of Rs. 160 per equity share declared by the Board at its meeting held on February 6, 2026), is Rs. 205 per equity share. 7. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the Labour Codes). The Labour Codes have been made effective from November 21 , 2025. The Ministry of Labour & Employment published Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. 8. The Company has evaluated the impact of the Labour Codes on the basis of information currently available. Management has assessed that the incremental impact, if any, of these changes are not material given that the current salary structure of the Company is in line with the requirements of the Labour Codes. The Company continues to monitor the finalisation of State Rules and clarifications from the Government on other aspects of the Labour Codes and would make appropriate adjustments, if needed. 9. The Company does not have a subsidiary, an associate or a joint venture as at 31st March, 2026. 10. The audited financial results are available on the website of the Company (www.pghealthindia.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com). 11. Previous year's / quarter's figures have been regrouped/ rearranged/reclassified wherever necessary to conform to current period's /quarter's classification.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 9,924.00
Capital work-in-progress 1,359.00
Investment property 251.00
Goodwill 0.00
Other intangible assets 47.00
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 0.00
Trade receivables, non-current
Loans, non-current 1,223.00
Other non-current financial assets
1 Other Financial Assets 484.00
2 Other non-current financial assets 4,302.00
3 Non Current tax assets 7,849.00
Total of other non-current financial assets 12,635.00
Total non-current financial assets 13,858.00
Deferred tax assets (net) 3,070.00
Other non-current assets
Total of other non-current assets
Total non-current assets 28,509.00
2 Current assets
Inventories 13,665.00
Current financial asset
Current investments 0.00
Trade receivables, current 16,426.00
Cash and cash equivalents 17,724.00
Bank balance other than cash and cash equivalents 805.00
Loans, current 209.00
Other current financial assets
Total of other current financial assets 1,617.00
Total current financial assets 36,781.00
Current tax assets (net) 0.00
Other current assets
1 Other Current Assets 5,024.00
2 Asset Held for Sale 156.00
Total of other current assets 5,180.00
Total current assets 55,626.00
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 84,135.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,660.00
Other equity 50,795.00
Total equity attributable to owners of parent 52,455.00
Non controlling interest
Total equity 52,455.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease Liabilities 572.00
2 Provisions 5,470.00
3 Other Non Current Financial Liabilities 145.00
Total of other non-current financial liabilities 6,187.00
Total non-current financial liabilities 6,187.00
Provisions, non-current 0.00
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 6,187.00
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 639.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 18,578.00
Total Trade payable 19,217.00
Other current financial liabilities
1 Lease Liabilities 357.00
2 Other Financial Liabilities 2,125.00
Total of other current financial liabilities 2,482.00
Total current financial liabilities 21,699.00
Other current liabilities 1,516.00
1 Other current liabilities 1,516.00
Total of other current liabilities 1,516.00
Provisions, current 1,401.00
Current tax liabilities (Net) 877.00
Deferred government grants, Current
Total current liabilities 25,493.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 31,680.00
Total equity and liabilites 84,135.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gains / (losses) on defined benefit plans (392.00) (38.00)
Total Amount of items that will not be reclassified to profit and loss (392.00) (38.00)
2 Income tax relating to items that will not be reclassified to profit or loss (99.00) (10.00)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income (293.00) (28.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 44,986.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 55.00
Adjustments for decrease (increase) in inventories (3,025.00)
Adjustments for decrease (increase) in trade receivables, current (1,481.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (2,878.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,955.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 3,089.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 2,359.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 66.00
Adjustments for dividend income 0.00
Adjustments for interest income 1,059.00
Adjustments for share-based payments 188.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items (91.00)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (822.00)
Net cash flows from (used in) operations 44,164.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 10,385.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 33,779.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 1,551.00
Proceeds from sales of investment property 118.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 1,056.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 503.00
Net cash flows from (used in) investing activities 126.00
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 0.00
Dividends paid 34,028.00
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (364.00)
Net cash flows from (used in) financing activities (34,392.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (487.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (487.00)
Cash and cash equivalents cash flow statement at beginning of period 18,227.00
Cash and cash equivalents cash flow statement at end of period 17,740.00





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Haribhakti & Co LLP Yes 31-07-2027


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HOME PRODUCTS PRIVATE LIMITED Group Company Any other transaction Affiliate Reimbursements payment Approved 864.31 0.00 0.00
2 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Any other transaction Affiliate Reimbursements payment Approved 513.62 0.00 0.00
3 PROCTER & GAMBLE HEALTH LIMITED GILLETTE DIVERSIFIED OPERATIONS PVT LTD Group Company Any other transaction Affiliate Reimbursements payment Approved 219.80 0.00 0.00
4 PROCTER & GAMBLE HEALTH LIMITED GILLETTE INDIA LIMITED Group Company Any other transaction Affiliate Reimbursements payment Approved 257.00 0.00 0.00
5 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Any other transaction Affiliate Reimbursements payment Approved 27.64 0.00 0.00
6 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HOME PRODUCTS PRIVATE LIMITED Group Company Any other transaction Affiliate Reimbursements payment Approved 5.94 0.00 0.00
7 PROCTER & GAMBLE HEALTH LIMITED THE PROCTER & GAMBLE COMPANY Ultimate Parent Company Any other transaction Affiliate Reimbursements payment Approved 63.62 0.00 0.00
8 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HOME PRODUCTS PRIVATE LIMITED Group Company Any other transaction Domestic – Cost sharing payment Approved 53.81 0.00 0.00
9 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Any other transaction Domestic – Cost sharing payment Approved 30.04 0.00 0.00
10 PROCTER & GAMBLE HEALTH LIMITED GILLETTE INDIA LIMITED Group Company Any other transaction Domestic – Cost sharing payment Approved 16.71 0.00 0.00
11 PROCTER & GAMBLE HEALTH LIMITED GILLETTE DIVERSIFIED OPERATIONS PVT LTD Group Company Any other transaction Domestic – Cost sharing payment Approved 6.87 0.00 0.00
12 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Purchase of goods or services Approved 934.63 0.00 0.00
13 PROCTER & GAMBLE HEALTH LIMITED THE PROCTER & GAMBLE U.S. BUSINESS SERVICES COMPANY Group Company Purchase of goods or services Approved 796.10 0.00 0.00
14 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE PHILIPPINES BUSINESS SERVICES, INC. Group Company Purchase of goods or services Approved 986.30 0.00 0.00
15 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA SINGAPOREBRANCH Group Company Purchase of goods or services Approved 388.50 0.00 0.00
16 PROCTER & GAMBLE HEALTH LIMITED Procter & Gamble Overseas India BV, The Netherlands Parent Company Dividend paid Approved 13,761.70 0.00 0.00
17 PROCTER & GAMBLE HEALTH LIMITED THE PROCTER & GAMBLE COMPANY Ultimate Parent Company Any other transaction Royalty Approved 1,407.70 0.00 0.00
18 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HOME PRODUCTS PRIVATE LIMITED Group Company Any other transaction Rent Approved 311.30 0.00 0.00
19 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Any other transaction Affiiliate reimbursement receipt Approved 39.03 0.00 0.00
20 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HOME PRODUCTS PRIVATE LIMITED Group Company Any other transaction Affiiliate reimbursement receipt Approved 223.95 0.00 0.00
21 PROCTER & GAMBLE HEALTH LIMITED GILLETTE DIVERSIFIED OPERATIONS PVT LTD Group Company Any other transaction Affiiliate reimbursement receipt Approved 873.00 0.00 0.00
22 PROCTER & GAMBLE HEALTH LIMITED GILLETTE INDIA LIMITED Group Company Any other transaction Affiiliate reimbursement receipt Approved 57.93 0.00 0.00
23 PROCTER & GAMBLE HEALTH LIMITED THE PROCTER & GAMBLE COMPANY Ultimate Parent Company Any other transaction Affiiliate reimbursement receipt Approved 24.61 0.00 0.00
24 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HOME PRODUCTS PRIVATE LIMITED Group Company Any other transaction Affiiliate reimbursement receipt Approved 36.28 0.00 0.00
25 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Any other transaction Affiiliate reimbursement receipt Approved 111.11 0.00 0.00
26 PROCTER & GAMBLE HEALTH LIMITED PT PROCTER & GAMBLE HOME PRODUCTS INDONESIA Group Company Any other transaction Affiiliate reimbursement receipt Approved 1.82 0.00 0.00
27 PROCTER & GAMBLE HEALTH LIMITED GILLETTE DIVERSIFIED OPERATIONS PVT LTD Group Company Any other transaction Affiiliate reimbursement receipt Approved 32.14 0.00 0.00
28 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA SINGAPOREBRANCH Group Company Any other transaction Affiiliate reimbursement receipt Approved 3.32 0.00 0.00
29 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE INTERNATIONAL OPERATIONS, SA Group Company Any other transaction Affiiliate reimbursement receipt Approved 5.97 0.00 0.00
30 PROCTER & GAMBLE HEALTH LIMITED P&G HEALTH AUSTRIA GMBH & CO. OG Group Company Sale of goods or services Approved 4,365.00 0.00 0.00
31 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Sale of fixed assets Approved 31.64 0.00 0.00
32 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HOME PRODUCTS PRIVATE LIMITED Group Company Sale of fixed assets Approved 64.52 0.00 0.00
33 PROCTER & GAMBLE HEALTH LIMITED GILLETTE DIVERSIFIED OPERATIONS PVT LTD Group Company Sale of fixed assets Approved 3.80 0.00 0.00
34 PROCTER & GAMBLE HEALTH LIMITED GILLETTE INDIA LIMITED Group Company Sale of fixed assets Approved 22.42 0.00 0.00
35 PROCTER & GAMBLE HEALTH LIMITED THE PROCTER & GAMBLE COMPANY Ultimate Parent Company Any other transaction R&D Approved 1,130.70 0.00 0.00
36 PROCTER & GAMBLE HEALTH LIMITED GILLETTE DIVERSIFIED OPERATIONS PVT LTD Group Company Any other transaction Rent received Approved 170.70 0.00 0.00
Total value of transaction during the reporting period 27,843.53